Biotech Values

[biotech_researcher]

AUPH- Maciste, I did, you may have read the whole HC Wainwright article:

"Two months ago, the drug maker realized a follow-on offering of 25.64M shares priced at $6.75 each, and received net proceeds of $162.3M. Aurinia’s management expects to have enough cash until 2020, which will be enough to cover expenses during Phase 3 trial and probably until the FDA approval for voclosporin. **However, the analyst projects another round of funding for Aurinia for U.S. commercial launch of the drug**"